The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation

Abstract Over the past few years, immune checkpoint inhibitors (ICIs) have greatly improved the survival for patients with non‐small cell lung cancer (NSCLC) without driver mutations. Compared with wild‐type tumors, tumors with epidermal growth factor receptor (EGFR) mutations show more heterogeneit...

Full description

Bibliographic Details
Main Authors: Lin Ma, Bowen Diao, Zhaoqin Huang, Bin Wang, Jinming Yu, Xiangjiao Meng
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:Cancer Communications
Subjects:
efficacy
EGFR mutation
immune checkpoint inhibitor
non‐small cell lung cancer
tumor microenvironment
Online Access:https://doi.org/10.1002/cac2.12229

Internet

https://doi.org/10.1002/cac2.12229

Similar Items